Nancy Lin, MD

Breast cancer specialist @DanaFarber; Director, EMBRACE MBC program. Tweets are my own and not medical advice.

[Dana-Farber’s Breast Oncology Center @DFCI_BreastOnc]

The DATO-BASE phase 2 trial is still actively recruiting patients in:

🔹 Cohort A: ER+/HER2− breast cancer with brain metastases

🔹 Cohort B: TNBC with brain metastases

More info & eligibility:
https://t.co/gNiwtxZv0q

@PTarantinoMD @nlinmd

[Nancy Lin, MD @nlinmd]

Excited to kick off our annual EMBRACE webinar series designed to educate and empower people living with metastatic breast cancer …

To see recordings from 2025-2026 and check out what is coming up in 2026-2027:

https://t.co/3wOFXLfgA9

[Dana-Farber’s Breast Oncology Center @DFCI_BreastOnc]

Watch the recording of the 2026–2027 EMBRACE #MetastaticBreastCancer Forum Series featuring Drs. Sara Tolaney (@stolaney1) and Nancy Lin (@nlinmd), as they discuss the latest developments and promising research in #MBC at @DanaFarber and beyond.

The presentation is followed by a Q&A moderated by Dr. Lexie Berwick.

https://t.co/jRfQRAU2ic

[Nancy Lin, MD @nlinmd]

Catch up on what’s current and new in treatment of ER+ metastatic breast cancer: part of our EMBRACE forum series, designed for people living with MBC.

[Dana-Farber’s Breast Oncology Center @DFCI_BreastOnc]

📽️Watch: The 2026–2027 EMBRACE Metastatic Breast Cancer Forum Series: Updates in ER-Positive #MBC.

Kristina Fanucci, MD, MHS, and Antonio Giordano, MD, PhD (@antgiorda), discuss treatment advances and research updates, followed by a Q&A moderated by Molly Skeffington. #MetastaticBreastCancer #BreastCancer #ERPositive

https://t.co/yAIrEUZXym

[Nancy Lin, MD @nlinmd]

Learn about current treatments and new options for HER2+ metastatic breast cancer: part of a patient-facing series designed to empower people living with MBC

[Dana-Farber’s Breast Oncology Center @DFCI_BreastOnc]

Adrienne Waks, MD (@adawaksmd), and Ilana Schlam, MD (@IlanaSchlam), present updates on current treatment approaches and emerging research in HER2-positive #MetastaticBreastCancer as part of the 2026–2027 EMBRACE #MBC Forum Series. Watch here:
https://t.co/dwG4RQavGp

[Harold J. Burstein, MD, PhD, FASCO @DrHBurstein]

Join us Tuesday, November 3rd at 2 PM Eastern time for a discussion of breast cancer updates from the ESMO 2026 meeting. Featuring remarkable @DanaFarber panel of @stolaney1 @elmayermd @antgiorda Ana Garrido-Castro, and myself. Hot takes, only!

Webinar is free but registration required at the link below.

https://t.co/h4ehKMx8t7

[Giampaolo Bianchini @BianchiniGP]

🔥 Good news for TNBC patients with brain mets!

Dato-DXd shows clinically meaningful activity in BMs

⚠️ Caveat: small TB02 subgroup, only half with active BMs (asymptomatic, untreated)

👉 Key message: after T-DXd, Dato-DXd also shows clear intracranial activity

#ESMO26

[Ilana Schlam @IlanaSchlam]

One more week to complete our survey! We want to understand what clinicians need to bring ctDNA MRD testing into routine clinical practice. If you care for patients with breast cancer, please take a few minutes to participate and help shape future research!

@nlinmd @stolaney1

[Nancy Lin, MD @nlinmd]

@Dr_R_Kurzrock Indeed! SWOG has just launched a study (S2511) testing multimodality therapy in the era of modern HER2 directed therapies for pts with oligometastatic HER2+ MBC.

https://t.co/xc1etzYpLE

[Nancy Lin, MD @nlinmd]

Yes! Pts w/MBC need:

-HER2+: effective tx post TDXD esp that treat/prevent brain mets

TNBC: effective tx post Trop2 x topo1 ADC. ADC are “better chemo” but we need game changers that transform the tail of the OS curve

ER+: options after 1L chemo when OS really starts to fall

[Dr Sarah Sammons @drsarahsam]

Our immense desire to move every successful therapy in metastatic breast cancer to front line is stifling innovation. Also the “me too” mentality of every company buying the same drug is a challenge.

Hi from the clinic,
We need new targets, new payloads, new 2L and 3L options in TNBC and HeR2+ MBC!

[Erika Hamilton, MD, FASCO @ErikaHamilton9]

10 new @FDA indications in #bcsm in 20 weeks - May to September, 2026.

Three firsts in there: first PROTAC in any cancer, first CDK4/6 inhibitor in HER2+ #bcsm, first drug approval triggered by ctDNA prior radiographic progression.

#clinicaltrials win! Patients win!

[Nancy Lin, MD @nlinmd]

I have really enjoyed working with Wassim on novel liquid biopsy technologies!

[Wassim Daoud Khatoun @WDKhatoun]

Hi #MedTwitter!

Excited to be applying to #InternalMedicine for #Match2027! 🩺

I’m a @lebamericanuni #IMG from 🇱🇧, currently a research fellow studying cancer epigenomics & liquid biopsy @DanaFarber @harvardmed.

AAMC ID: 14999066

Grateful for everyone who made this possible!

[Nancy Lin, MD @nlinmd]

Very cool approach leveraging LLM to characterize toxicity and correlate with GWAS at a scale that allows discovery of novel associations!

[Sasha Gusev @SashaGusevPosts]

Tour de force characterizing therapy toxicity in cancer at very large scale!

[Komal Jhaveri, MD, FACP, FASCO @jhaveri_komal]

Grateful for the growing options to treat ESR1-mutated tumors. This combination was NCCN endorsed and now FDA approved. This pace of progress is exciting for our patients — but our work is far from done! @MSKCancerCenter @OncoAlert #bcsm

[Dana-Farber’s Breast Oncology Center @DFCI_BreastOnc]

📣We are leading a study on the use of #ctDNA NGS and MRD Assays in Clinical Practice.

If you are a licensed clinician who treats patients with #BreastCancer, help us better understand current practice patterns and perceptions regarding the use of circulating tumor DNA (ctDNA) standard next-generation sequencing (#NGS) assays and minimal residual disease (#MRD) assays in breast cancer, across both early-stage and metastatic settings.

Our goal is to identify how these tools are currently being used, the perceived barriers to their implementation, and the evidence or resources needed to support the integration of ctDNA testing into routine clinical practice.

Thank you in advance for taking our short (10-15 minutes) questionnaire!
👉Link: https://t.co/eG5gZbc2cE

For more info: [email protected]
#BreastCancerResearch #BloodTest #BloodBiopsy
PI: Ilana Schlam (@IlanaSchlam)

[Nancy Lin, MD @nlinmd]

Brilliant keynote from @HendriksLizza - ‘Breaking Barriers, Redefining Brain Metastases Treatment Concepts” at #snoasco2026

-identifying pts at high risk
-optimizing tx and sequencing
-access- trials, molecular testing, drugs, knowledge
-multiD teamwork and collaborations

[SNO @NeuroOnc]

We are looking forward to a full day of dynamic presentations and discussions at this year’s SNO/ASCO CNS Metastases Conference. Co-chairs Jona Hattangadi-Gluth and Jarushka Naidoo kick-off the “From Moonshot to Groundshot: Transforming Science into Impact” meeting. #SNOASCO2026

[Dana-Farber’s Breast Oncology Center @DFCI_BreastOnc]

Join the EMBRACE Program for a day of wellness, education, and community building! Hosted in collaboration with Dana-Farber’s Zakim Center for Integrative Therapies and Healthy Living, this free event will include tai chi, massage, ear acupuncture, expressive arts, mindful movement, and more.

Open to adults living with #MetastaticBreastCancer and their loved ones. #MBC

🗓️ Wednesday, September 9 | 10 a.m. - 3:30 p.m. ET
📍 Dana-Farber Cancer Institute, 450 Brookline Ave., Boston, MA

Register today ➡️ https://t.co/5MoIqGNV71

[Nancy Lin, MD @nlinmd]

Such a beautiful story.

Gleevec made the impossible possible. I remember the moment when people with CML no longer filled our bone marrow transplant units, because a small pill transformed their lives.

The power of science + humanity + clinical trials. ❤️🙏

[Mel Mann, MBA, M.Ed @MelDMann]

31 years ago I was diagnosed with terminal #cancer.

No cure. Three years to live. I recruited many thousands of potential bone marrow donors, but never found one for myself.

My daughter was 5 years old when I was diagnosed. Because of a miracle, I was able to see her grow up, go to #Harvard & become a board certified physician.

In 2015 I shared my clinical trial miracle story. That one post hit 7 million impressions.

I’m still here. The World’s longest-living #Gleevec survivor. Clinical trials rewrote my ending.

Original post:
https://t.co/Mo37VMNvBX
Share if you know someone who needs this hope today! ❤️
#CML #ClinicalTrials #CancerSurvivor

[Sara Tolaney @stolaney1]

Team Duncan is truly amazing!! Congrats to the team, and thank you for all the support for breast oncology research!! It means so much to the work we can do to try + improve patient outcomes!

@DFCI_BreastOnc @PhilipPoorvu

[Dana-Farber’s Breast Oncology Center @DFCI_BreastOnc]

📢 Social and support opportunities for adults diagnosed with stage IV metastatic breast cancer under the age of 45

Whether you are interested in connecting with other young adults who “get it” from time to time or building a new network of support, EMBRACing Young and Strong socials are a great way to meet and connect with others who were diagnosed under the age of 45.

📅 Thursdays | 6:30 – 7:45 PM ET
➤ July 30: Cooking Demo
➤ Aug 20: Lymph Flow Yoga

🔗 To learn more and register, please visit: https://t.co/xBAGCiwnX3